FOLFOXIRI + bevacizumab + mitomycin

FOLFOXIRI + bevacizumab + mitomycin is an investigational combination chemotherapy regimen used primarily in the treatment of metastatic colorectal cancer (mCRC). The regimen combines: - **FOLFOXIRI** (a four-drug chemotherapy backbone consisting of folinic acid [leucovorin], fluorouracil [5-FU], oxaliplatin, and irinotecan), which targets rapidly dividing cancer cells through multiple mechanisms including DNA crosslinking, inhibition of topoisomerase I, and antimetabolite activity. - **Bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis required for tumor growth. - **Mitomycin**, an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and function. This intensive combination aims to maximize cytotoxic effects on tumor cells while also inhibiting the formation of new blood vessels necessary for tumor progression. FOLFOXIRI plus bevacizumab has demonstrated improved response rates and survival outcomes compared to doublet regimens in mCRC[3][4][5]. The addition of mitomycin is less common but may be explored in specific clinical trial settings or as part of salvage therapy protocols.

Other names

FOLFOXIRI plus bevacizumab plus mitomycin